143 related articles for article (PubMed ID: 36149404)
1. Effect of Dopaminergic Therapy on Impulse Control Disorders in Patients With a Prolactinoma.
Ozdeniz Varan E; Gurvit H
Cogn Behav Neurol; 2023 Mar; 36(1):1-8. PubMed ID: 36149404
[TBL] [Abstract][Full Text] [Related]
2. Dopamine Agonist-Induced Impulse Control Disorders in Patients With Prolactinoma: A Cross-Sectional Multicenter Study.
Dogansen SC; Cikrikcili U; Oruk G; Kutbay NO; Tanrikulu S; Hekimsoy Z; Hadzalic A; Gorar S; Omma T; Mert M; Akbaba G; Yalin GY; Bayram F; Ozkan M; Yarman S
J Clin Endocrinol Metab; 2019 Jul; 104(7):2527-2534. PubMed ID: 30848825
[TBL] [Abstract][Full Text] [Related]
3. Impulse Control Disorders in Patients with Pituitary Tumors Treated with Dopamine Agonists: A Systematic Review.
Hamblin R; Karavitaki N
Arch Med Res; 2023 Dec; 54(8):102910. PubMed ID: 37985276
[TBL] [Abstract][Full Text] [Related]
4. Impulse control disorders in patients with prolactinoma receiving dopamine agonist therapy: a prospective study with 1 year follow-up.
Celik E; Ozkaya HM; Poyraz BC; Saglam T; Kadioglu P
Endocrine; 2018 Dec; 62(3):692-700. PubMed ID: 30206771
[TBL] [Abstract][Full Text] [Related]
5. Dopamine Agonists and Impulse Control Disorders: A Complex Association.
Grall-Bronnec M; Victorri-Vigneau C; Donnio Y; Leboucher J; Rousselet M; Thiabaud E; Zreika N; Derkinderen P; Challet-Bouju G
Drug Saf; 2018 Jan; 41(1):19-75. PubMed ID: 28861870
[TBL] [Abstract][Full Text] [Related]
6. The side effects of dopamine receptor agonist drugs in Chinese prolactinoma patients: a cross sectional study.
Ke X; Wang L; Chen M; Liu S; Yu N; Duan L; Gong F; Zhu H
BMC Endocr Disord; 2022 Apr; 22(1):97. PubMed ID: 35410236
[TBL] [Abstract][Full Text] [Related]
7. Patients with acromegaly might not be at higher risk for dopamine agonist-induced impulse control disorders than those with prolactinomas.
Ozkaya HM; Sahin S; Korkmaz OP; Durcan E; Sahin HR; Celik E; Poyraz BC; Kadioglu P
Growth Horm IGF Res; 2020 Dec; 55():101356. PubMed ID: 33010581
[TBL] [Abstract][Full Text] [Related]
8. Impulse control disorders in patients with dopamine agonist-treated pituitary adenomas: a cross-sectional multicenter study.
Almalki MH; Alsuraikh MA; Almalki E; Aziz F; Almazrouei R; AlDahmani KM; Alshahrani F; Alaqeel M; Mahzari M; Ekhzaimy A
Pituitary; 2024 Apr; 27(2):197-203. PubMed ID: 38345719
[TBL] [Abstract][Full Text] [Related]
9. Impulse control disorders in hyperprolactinemic patients on dopamine agonist therapy.
Hamidianjahromi A; Tritos NA
Rev Endocr Metab Disord; 2022 Oct; 23(5):1089-1099. PubMed ID: 36125673
[TBL] [Abstract][Full Text] [Related]
10. Impulse control disorders in patients with dopamine agonist-treated prolactinomas and nonfunctioning pituitary adenomas: a case-control study.
Bancos I; Nannenga MR; Bostwick JM; Silber MH; Erickson D; Nippoldt TB
Clin Endocrinol (Oxf); 2014 Jun; 80(6):863-8. PubMed ID: 24274365
[TBL] [Abstract][Full Text] [Related]
11. Dopamine agonist-induced impulse control disorders in a patient with prolactinoma.
Almanzar S; Zapata-Vega MI; Raya JA
Psychosomatics; 2013; 54(4):387-91. PubMed ID: 23261076
[No Abstract] [Full Text] [Related]
12. Depression and Impulsivity Self-Assessment Tools to Identify Dopamine Agonist Side Effects in Patients With Pituitary Adenomas.
Hinojosa-Amaya JM; Johnson N; González-Torres C; Varlamov EV; Yedinak CG; McCartney S; Fleseriu M
Front Endocrinol (Lausanne); 2020; 11():579606. PubMed ID: 33193096
[No Abstract] [Full Text] [Related]
13. Impulse Control Disorders with Short-term Use of Cabergoline in Macroprolactinomas: A Prospective Study with a Brief Review of Literature.
Sanjan G; Das L; Ahuja CK; Dhandapani S; Sachdeva N; Grover S; Dutta P
Neurol India; 2023; 71(1):107-112. PubMed ID: 36861582
[TBL] [Abstract][Full Text] [Related]
14. Treating prolactinomas with dopamine agonists: always worth the gamble?
Noronha S; Stokes V; Karavitaki N; Grossman A
Endocrine; 2016 Feb; 51(2):205-10. PubMed ID: 26336835
[TBL] [Abstract][Full Text] [Related]
15. A Genetic Assessment of Dopamine Agonist-Induced Impulse Control Disorder in Patients With Prolactinoma.
Sahin S; Sudutan T; Kavla Y; Durcan E; Özogul YY; Poyraz BC; Sayitoglu M; Ozkaya HM; Kadioglu P
J Clin Endocrinol Metab; 2023 May; 108(6):e275-e282. PubMed ID: 36494095
[TBL] [Abstract][Full Text] [Related]
16. Impulse control disorders associated with dopaminergic medication in patients with pituitary adenomas.
Martinkova J; Trejbalova L; Sasikova M; Benetin J; Valkovic P
Clin Neuropharmacol; 2011; 34(5):179-81. PubMed ID: 21738024
[TBL] [Abstract][Full Text] [Related]
17. Decision-making, reward-seeking behaviors and dopamine agonist therapy in restless legs syndrome.
Bayard S; Langenier MC; Dauvilliers Y
Sleep; 2013 Oct; 36(10):1501-7. PubMed ID: 24082309
[TBL] [Abstract][Full Text] [Related]
18. Risk of impulse control disorders in patients with Cushing's disease: do not blame cabergoline but do not give up caution.
Sulu C; Gul N; Tanrikulu S; Ciftci S; Yener Ozturk F; Sarac B; Ersungur EB; Tanriover E; Sahin S; Ozkaya HM; Poyraz BC; Kadioglu P
Pituitary; 2023 Aug; 26(4):495-509. PubMed ID: 37474846
[TBL] [Abstract][Full Text] [Related]
19. Association of dopamine agonist use with impulse control disorders in Parkinson disease.
Weintraub D; Siderowf AD; Potenza MN; Goveas J; Morales KH; Duda JE; Moberg PJ; Stern MB
Arch Neurol; 2006 Jul; 63(7):969-73. PubMed ID: 16831966
[TBL] [Abstract][Full Text] [Related]
20. Impulse control disorder in a patient on long-term treatment with bromocriptine for a macroprolactinoma.
Thondam SK; Alusi S; O'Driscoll K; Gilkes CE; Cuthbertson DJ; Daousi C
Clin Neuropharmacol; 2013; 36(5):170-2. PubMed ID: 24045609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
